methacetin has been researched along with Hepatitis in 2 studies
methacetin: RN given refers to parent cpd
methacetin : A member of the class of acetamides that is paracetamol in which the hydrogen of phenolic hydroxy group has been replaced by a methyl group.
Hepatitis: INFLAMMATION of the LIVER.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (50.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lalazar, G | 1 |
Adar, T | 1 |
Ilan, Y | 1 |
Qiu, YY | 1 |
Tang, ZD | 1 |
Xia, ZQ | 1 |
Dai, TC | 1 |
Hu, YE | 1 |
Li, J | 1 |
Lu, YJ | 1 |
Zhang, NL | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
13C-Methacetin Breath Test for the Prediction of Outcome in in Acute Liver Injury or Acute Liver Failure[NCT02786836] | Phase 2/Phase 3 | 76 participants (Actual) | Interventional | 2016-06-10 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The relationship between the cPDR (cumulative PDR of metabolized 13C-Methacetin 20 minutes after ingestion) in single time points of MBT measurements and TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
Intervention | percentage per hour (Mean) | |
---|---|---|
Day 1 or 2 MBT/transplant free survival at Day 21 | Day 1 or 2 MBT & Day 21 non-TFS | |
13C-Methacetin Breath Test (MBT) | 1.4 | 0.2 |
Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 (normal carbon dioxide) ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS (transplant free survival) and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: Days 1 and 21
Intervention | percentage per hour (Mean) | |
---|---|---|
Mean Peak PDR for TFS subjects at Day 21 | Mean Peak PDR for non-TFS subjects at Day 21 | |
13C-Methacetin Breath Test (MBT) | 10.2 | 1.9 |
This outcome is similar to the peak PDR defined in the primary outcome but as a secondary we are looking at Day 1 or Day 2 peak PDR values. Peak PDR is the maximal percent dose recovery (PDR) rate which reflects the maximum rate of metabolism of 13C-methacetin measured as the change in 13CO2 / 12CO2 ratio after ingestion of 13C-methacetin normalized using the patient's height and weight. The distributions of mean PDR Peak values were compared between TFS and non-TFS (death/transplant) at Day 21. (NCT02786836)
Timeframe: The first MBT reading either on Day 1 or Day 2 and Day 21
Intervention | percentage per hour (Mean) | |
---|---|---|
Day 1 or 2 MBT & Day 21 TFS | Day 1 or 2 MBT & Day 21 non-TFS | |
13C-Methacetin Breath Test (MBT) | 9.1 | 2.3 |
1 trial available for methacetin and Hepatitis
Article | Year |
---|---|
Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial.
Topics: Acetamides; Acute Disease; Adolescent; Adult; Breath Tests; Carbon Isotopes; Female; Hepatitis; Hepa | 2009 |
1 other study available for methacetin and Hepatitis
Article | Year |
---|---|
Diagnostic value of C-13-methacetin breath test in liver diseases.
Topics: Acetamides; Breath Tests; Carbon Isotopes; Hepatic Encephalopathy; Hepatitis; Humans; Liver Cirrhosi | 1988 |